220 related articles for article (PubMed ID: 19650625)
1. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9.
Yu D; Wang D; Zhu FG; Bhagat L; Dai M; Kandimalla ER; Agrawal S
J Med Chem; 2009 Aug; 52(16):5108-14. PubMed ID: 19650625
[TBL] [Abstract][Full Text] [Related]
2. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9.
Wang D; Bhagat L; Yu D; Zhu FG; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2009 Jan; 52(2):551-8. PubMed ID: 19102653
[TBL] [Abstract][Full Text] [Related]
3. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
4. Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.
Yu D; Putta MR; Bhagat L; Li Y; Zhu F; Wang D; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2007 Dec; 50(25):6411-8. PubMed ID: 17988082
[TBL] [Abstract][Full Text] [Related]
5. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
6. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.
Yu D; Putta MR; Bhagat L; Dai M; Wang D; Trombino AF; Sullivan T; Kandimalla ER; Agrawal S
Antimicrob Agents Chemother; 2008 Dec; 52(12):4320-5. PubMed ID: 18852281
[TBL] [Abstract][Full Text] [Related]
7. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
8. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM
Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717
[TBL] [Abstract][Full Text] [Related]
9. Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses.
Putta MR; Yu D; Bhagat L; Wang D; Zhu FG; Kandimalla ER
J Med Chem; 2010 May; 53(9):3730-8. PubMed ID: 20361743
[TBL] [Abstract][Full Text] [Related]
10. Synthetic agonists of Toll-like receptors 7, 8 and 9.
Agrawal S; Kandimalla ER
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1461-7. PubMed ID: 18031246
[TBL] [Abstract][Full Text] [Related]
11. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens.
Andersen JM; Al-Khairy D; Ingalls RR
Biol Reprod; 2006 May; 74(5):824-31. PubMed ID: 16421230
[TBL] [Abstract][Full Text] [Related]
12. Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity.
Putta MR; Zhu FG; Wang D; Bhagat L; Dai M; Kandimalla ER; Agrawal S
Bioconjug Chem; 2010 Jan; 21(1):39-45. PubMed ID: 20020767
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.
Kandimalla ER; Bhagat L; Li Y; Yu D; Wang D; Cong YP; Song SS; Tang JX; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2005 May; 102(19):6925-30. PubMed ID: 15860583
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists.
Jurk M; Kritzler A; Debelak H; Vollmer J; Krieg AM; Uhlmann E
ChemMedChem; 2006 Sep; 1(9):1007-14. PubMed ID: 16952134
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.
Schlaepfer E; Audigé A; von Beust B; Manolova V; Weber M; Joller H; Bachmann MF; Kundig TM; Speck RF
J Virol; 2004 Nov; 78(22):12344-54. PubMed ID: 15507621
[TBL] [Abstract][Full Text] [Related]
16. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.
Vollmer J; Weeratna RD; Jurk M; Samulowitz U; McCluskie MJ; Payette P; Davis HL; Schetter C; Krieg AM
Immunology; 2004 Oct; 113(2):212-23. PubMed ID: 15379982
[TBL] [Abstract][Full Text] [Related]
17. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
Lan T; Dai M; Wang D; Zhu FG; Kandimalla ER; Agrawal S
J Med Chem; 2009 Nov; 52(21):6871-9. PubMed ID: 19824640
[TBL] [Abstract][Full Text] [Related]
19. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis.
Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z
J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
